Geriatric Nutritional Risk Index is a predictor of tolerability of antifibrotic therapy and mortality risk in patients with idiopathic pulmonary fibrosis

被引:22
作者
Mochizuka, Yasutaka [1 ]
Suzuki, Yuzo [1 ]
Kono, Masato [2 ]
Hasegawa, Hirotsugu [3 ]
Hashimoto, Dai [2 ]
Yokomura, Koshi [3 ]
Inoue, Yusuke [1 ]
Yasui, Hideki [1 ]
Hozumi, Hironao [1 ]
Karayama, Masato [1 ]
Furuhashi, Kazuki [1 ]
Enomoto, Noriyuki [1 ]
Fujisawa, Tomoyuki [1 ]
Inui, Naoki [1 ]
Nakamura, Hidenori [2 ]
Suda, Takafumi [1 ]
机构
[1] Hamamatsu Univ, Dept Internal Med, Div 2, Sch Med, Hamamatsu, Japan
[2] Seirei Hamamatsu Gen Hosp, Dept Resp Med, Hamamatsu, Japan
[3] Seirei Mikatahara Gen Hosp, Dept Resp Med, Hamamatsu, Japan
基金
日本学术振兴会;
关键词
antifibrotic therapy; Geriatric Nutritional Risk Index; idiopathic pulmonary fibrosis; malnutrition-related risk; mortality; tolerability; PIRFENIDONE; DIAGNOSIS; EFFICACY;
D O I
10.1111/resp.14523
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background and ObjectiveIdiopathic pulmonary fibrosis (IPF) is characterized by progressive lung fibrosis of unknown aetiology. Epidemiological studies have suggested that IPF progression may negatively affect nutritional status. Weight loss during antifibrotic therapy is also frequently encountered. The association of nutritional status and outcome has not been fully evaluated in IPF patients. MethodsThis retrospective multicohort study assessed nutritional status of 301 IPF patients receiving antifibrotic therapy (Hamamatsu cohort, n = 151; Seirei cohort, n = 150). Nutritional status was evaluated using the Geriatric Nutritional Risk Index (GNRI). The GNRI was calculated based on body mass index and serum albumin. The relationship between nutritional status and tolerability of antifibrotic therapy as well as mortality was explored. ResultsOf 301 patients, 113 (37.5%) had malnutrition-related risk (GNRI < 98). Patients with malnutrition-related risk were older, had increased exacerbations and worse pulmonary function than those without a GNRI status <98. Malnutrition-related risk was associated with a higher incidence of discontinuation of antifibrotic therapy, particulary due to gastrointestinal disturbances. IPF patients with malnutrition-related risk (GNRI < 98) had shorter survival than those without such risk (median survival: 25.9 vs. 41.1 months, p < 0.001). In multivariate analysis, malnutrition-related risk was a prognostic indicator of antifibrotic therapy discontinuation and mortality, independent of age, sex, forced vital capacity, or gender-age-physiology index. ConclusionNutritional status has significant effects on the treatment and outcome in patients with IPF. Assessment of nutritional status may provide important information for managing patients with IPF.
引用
收藏
页码:775 / 783
页数:9
相关论文
共 40 条
[21]  
Prytherch DR, 1998, BRIT J SURG, V85, P1217
[22]   Weight loss as a predictor of mortality in patients with interstitial lung disease [J].
Pugashetti, Janelle ;
Graham, Julia ;
Boctor, Noelle ;
Mendez, Cesar ;
Foster, Elena ;
Juarez, Maya ;
Harper, Richart ;
Morrissey, Brian ;
Kadoch, Michael ;
Oldham, Justin M. .
EUROPEAN RESPIRATORY JOURNAL, 2018, 52 (03)
[23]   Diagnosis of Idiopathic Pulmonary Fibrosis An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline [J].
Raghu, Ganesh ;
Remy-Jardin, Martine ;
Myers, Jeffrey L. ;
Richeldi, Luca ;
Ryerson, Christopher J. ;
Lederer, David J. ;
Behr, Juergen ;
Cottin, Vincent ;
Danoff, Sonye K. ;
Morell, Ferran ;
Flaherty, Kevin R. ;
Wells, Athol ;
Martinez, Fernando J. ;
Azuma, Arata ;
Bice, Thomas J. ;
Bouros, Demosthenes ;
Brown, Kevin K. ;
Collard, Harold R. ;
Duggal, Abhijit ;
Galvin, Liam ;
Inoue, Yoshikazu ;
Jenkins, R. Gisli ;
Johkoh, Takeshi ;
Kazerooni, Ella A. ;
Kitaichi, Masanori ;
Knight, Shandra L. ;
Mansour, George ;
Nicholson, Andrew G. ;
Pipavath, Sudhakar N. J. ;
Buendia-Roldan, Ivette ;
Selman, Moises ;
Travis, William D. ;
Walsh, Simon ;
Wilson, Kevin C. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 198 (05) :E44-E68
[24]   An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline [J].
Raghu, Ganesh ;
Rochwerg, Bram ;
Zhang, Yuan ;
Garcia, Carlos A. Cuello ;
Azuma, Arata ;
Behr, Juergen ;
Brozek, Jan L. ;
Collard, Harold R. ;
Cunningham, William ;
Homma, Sakae ;
Johkoh, Takeshi ;
Martinez, Fernando J. ;
Myers, Jeffrey ;
Protzko, Shandra L. ;
Richeldi, Luca ;
Rind, David ;
Selman, Moises ;
Theodore, Arthur ;
Wells, Athol U. ;
Hoogsteden, Henk ;
Schuenemann, Holger J. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 192 (02) :E3-E19
[25]   An Official ATS/ERSARS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management [J].
Raghu, Ganesh ;
Collard, Harold R. ;
Egan, Jim J. ;
Martinez, Fernando J. ;
Behr, Juergen ;
Brown, Kevin K. ;
Colby, Thomas V. ;
Cordier, Jean-Francois ;
Flaherty, Kevin R. ;
Lasky, Joseph A. ;
Lynch, David A. ;
Ryu, Jay H. ;
Swigris, Jeffrey J. ;
Wells, Athol U. ;
Ancochea, Julio ;
Bouros, Demosthenes ;
Carvalho, Carlos ;
Costabel, Ulrich ;
Ebina, Masahito ;
Hansell, David M. ;
Johkoh, Takeshi ;
Kim, Dong Soon ;
King, Talmadge E., Jr. ;
Kondoh, Yasuhiro ;
Myers, Jeffrey ;
Mueller, Nestor L. ;
Nicholson, Andrew G. ;
Richeldi, Luca ;
Selman, Moises ;
Dudden, Rosalind F. ;
Griss, Barbara S. ;
Protzko, Shandra L. ;
Schuenemann, Holger J. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183 (06) :788-824
[26]   Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis [J].
Richeldi, Luca ;
Kolb, Martin ;
Jouneau, Stephane ;
Wuyts, Wim A. ;
Schinzel, Birgit ;
Stowasser, Susanne ;
Quaresma, Manuel ;
Raghu, Ganesh .
BMC PULMONARY MEDICINE, 2020, 20 (01)
[27]   Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis [J].
Richeldi, Luca ;
du Bois, Roland M. ;
Raghu, Ganesh ;
Azuma, Arata ;
Brown, Kevin K. ;
Costabel, Ulrich ;
Cottin, Vincent ;
Flaherty, Kevin R. ;
Hansell, David M. ;
Inoue, Yoshikazu ;
Kim, Dong Soon ;
Kolb, Martin ;
Nicholson, Andrew G. ;
Noble, Paul W. ;
Selman, Moises ;
Taniguchi, Hiroyuki ;
Brun, Michele ;
Le Maulf, Florence ;
Girard, Mannaig ;
Stowasser, Susanne ;
Schlenker-Herceg, Rozsa ;
Disse, Bernd ;
Collard, Harold R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (22) :2071-2082
[28]   Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis [J].
Richeldi, Luca ;
Costabel, Ulrich ;
Selman, Moises ;
Kim, Dong Soon ;
Hansell, David M. ;
Nicholson, Andrew G. ;
Brown, Kevin K. ;
Flaherty, Kevin R. ;
Noble, Paul W. ;
Raghu, Ganesh ;
Brun, Michele ;
Gupta, Abhya ;
Juhel, Nolwenn ;
Klueglich, Matthias ;
du Bois, Roland M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (12) :1079-1087
[29]   The antioxidant properties of serum albumin [J].
Roche, Mariolaine ;
Rondeau, Philippe ;
Singh, Nihar Ranjan ;
Tarnus, Evelyne ;
Bourdon, Emmanuel .
FEBS LETTERS, 2008, 582 (13) :1783-1787
[30]   Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis [J].
Suzuki, Yuzo ;
Mori, Kazutaka ;
Aono, Yuya ;
Kono, Masato ;
Hasegawa, Hirotsugu ;
Yokomura, Koshi ;
Naoi, Hyogo ;
Hozumi, Hironao ;
Karayama, Masato ;
Furuhashi, Kazuki ;
Enomoto, Noriyuki ;
Fujisawa, Tomoyuki ;
Nakamura, Yutaro ;
Inui, Naoki ;
Nakamura, Hidenori ;
Suda, Takafumi .
SCIENTIFIC REPORTS, 2021, 11 (01)